Table 3.
Neoadjuvant trials in HER2-positive primary breast cancer
| Trial |
|||||||
|---|---|---|---|---|---|---|---|
| NeoSphere | NeoALTTO | GeparQuinto | GeparQuattro | Techno | MD Anderson | NOAH | |
| CHT | Doc | Pac | EC-Doc | EC-Doc ± Cap | EC-Pacb | Pac-FEC | APac-Pac-CMF |
| Duration, weeks | 12 | 12+6a | 24 | 24/36 | 24 | 24 | 33 |
| CHT + Tra | |||||||
| n | 107 | 149 | 309 | 445 | 217 | 23 | 117 |
| pCRc rate, % | 21.5 | 27.6 | 44.6 | 40.0 | 39.0 | 65.2 | 38.0 |
| CHT + 2 anti-HER2 agents | |||||||
| Agents | Tra + Per | Tra + Lap | |||||
| n | 107 | 152 | |||||
| pCRrate, % | 39.3 | 46.9 | |||||
CHT = Chemotherapy; Doc = docetaxel; Pac = paclitaxel; EC = epirubicine, cyclophospamide; Cap = capecitabine; FEC = 5-fluorouracil, epirubicine, cyclophospamide; A = adriamycin; Tra = trastuzumab; Per = pertuzumab; Lap = lapatinib; CMF = cyclophosphamide, methotrexate, fluorouracil.
a
Treatment started with 6 weeks anti-HER2 therapy alone followed by the addition of paclitaxel for 12 weeks.
b
Tra only added to Pac.
c
pCR defined as ypTO/pTisypNO.